Cynosure (CYNO) versus Its Competitors Financial Survey
Cynosure (NASDAQ: CYNO) is one of 87 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Cynosure to related businesses based on the strength of its earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Institutional & Insider Ownership
51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 2.9% of Cynosure shares are held by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings for Cynosure and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure currently has a consensus target price of $58.00, indicating a potential upside of Infinity. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.71%. Given Cynosure’s higher possible upside, equities research analysts plainly believe Cynosure is more favorable than its competitors.
This table compares Cynosure and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Cynosure and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cynosure Competitors||$2.13 billion||$221.25 million||2.53|
Cynosure’s competitors have higher revenue and earnings than Cynosure. Cynosure is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Cynosure competitors beat Cynosure on 6 of the 10 factors compared.
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.